PAA 3.13% 16.5¢ pharmaust limited

Ann: Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells, page-138

  1. 8,866 Posts.
    lightbulb Created with Sketch. 1713
    Go back to the announcement 24 June in which they stated the next step was producing a Executive Summary, nothing about waiting for any further testing.
    Quarterly annou cement in July they added they needed to wait for analysis assays prior to producing the executive summary, i assume that the August announcements were based around these assays but nothing said about producing the executive summary but What do we get told that further trials are required.
    Any wonder I say very little progress, same stuffing around now as its been since 2015.
    Do the BOD have any idea what they are doing.
    Canine dossier 6 months late on delivery, human cancer trials being run at same time as canine trials were were told was to risky, but the question is why nothing prepared between January to now in relation to human cancer trials.

    One delay after another for no apparent reason
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
16.5¢
Change
0.005(3.13%)
Mkt cap ! $80.22M
Open High Low Value Volume
16.5¢ 17.5¢ 16.5¢ $276.1K 1.636M

Buyers (Bids)

No. Vol. Price($)
4 379426 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.0¢ 10000 1
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.